Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration

Table 2

Primary and secondary outcomes.

Outcome	Nucleocapsid protein			RBD			S1 subunit
	High ab conc. (N = 51)	Low ab conc. (N = 45)	value	High ab conc. (N = 48)	Low ab conc. (N = 48)	value	High ab conc. (N = 48)	Low ab conc. (N = 48)	value
Primary outcome
30-day mortality—no. (%)	12 (23.5)	10 (22.2)	0.88	11(22.9)	11(22.9)	1.00	9(18.8)	13(27.1)	0.33
Secondary outcomes
Subsequent receipt of invasive ventilation in previously nonventilated—no. (%)	8/42 (19.0)	9/38 (23.7)	0.61	9/41 (22.0)	8/39 (20.5)	0.88	9/43 (20.9)	8/37 (21.6)	0.94
Length of hospital stay	14.2 ± 8.2	18.3 ± 13.3	0.07	15.2 ± 8.2	17.0 ± 13.3	0.42	14.9 ± 8.0	17.4 ± 13.4	0.26
Number of ventilator days (including those who subsequently received mechanical ventilation)	12.3 ± 8.11	19.8 ± 14.98	0.08	12.8 ± 8.3	18.9 ± 14.9	0.16	12.8 ± 8.3	18.3 ± 14.4	0.21
Overall mortality based on time to transfusion to death/end of cohort observation period
30-day mortality based on time from symptom onset to plasma transfusion—no. (%)
Infusion <10 days	14/67 (20.9)
Infusion >/ = 10 days	8/29 (27.6)

Plus–minus values are means ± SD.